MicroRNAs are short, non-coding RNA molecules, typically only about twenty-two nucleotides long, that do not carry instructions for making proteins. Instead, they act as fine-tuners of gene expression. After being transcribed from the genome and processed into their mature form, microRNAs are loaded into the RNA-induced silencing complex, a molecular machine that scans messenger RNAs for complementary sequences. When a match is found, the complex either destroys the messenger RNA or blocks its translation into protein. A single microRNA can regulate dozens or even hundreds of different target genes, which places these molecules at critical control points in cellular biology, including inflammation, cell proliferation, and the formation of new blood vessels. Because microRNAs are remarkably stable in blood and other body fluids, they have attracted intense interest as potential liquid biopsy markers for diseases ranging from cancer to neurodegeneration.

The research team, led by Huiqing Guo of the Department of Ophthalmology at the First Affiliated Hospital of Henan Medical University, enrolled seventy patients with type 2 diabetes mellitus but no retinopathy and 136 patients with diabetic retinopathy in the clinical portion of the study. The researchers measured miR-362-5p expression and then applied a battery of statistical tools, including receiver operating characteristic curve analysis, logistic regression, and correlation analysis, to determine whether the microRNA could serve as a diagnostic marker and how its levels related to standard clinical measurements. The results were striking: patients with diabetic retinopathy showed clearly upregulated miR-362-5p compared with the diabetes-only group, and the molecule’s levels correlated with fasting blood glucose, two-hour oral glucose tolerance test values, glycated hemoglobin, and best corrected visual acuity measured on the logMAR scale.

Receiver operating characteristic analysis, a standard method for judging diagnostic performance by plotting sensitivity against the false positive rate, indicated that miR-362-5p could function as a candidate diagnostic biomarker for diabetic retinopathy. Perhaps even more intriguingly, the researchers found that miR-362-5p expression rose further in patients with proliferative diabetic retinopathy, the advanced stage of the disease in which abnormal new blood vessels grow on the retinal surface, compared with patients who had the non-proliferative form. This suggests the microRNA may not merely flag the presence of retinopathy but could help clinicians distinguish early disease from the sight-threatening proliferative stage, a distinction that currently often requires detailed retinal imaging and expert interpretation.

To understand what miR-362-5p is actually doing inside retinal tissue, the team turned to the laboratory bench. They built an in vitro model of diabetic retinopathy by exposing human retinal microvascular endothelial cells to high glucose concentrations, mimicking the metabolic stress that these cells endure in patients with poorly controlled diabetes. Retinal microvascular endothelial cells form the inner lining of the tiny vessels that nourish the retina, and their dysfunction is considered a central event in the pathogenesis of diabetic retinopathy. Under chronic high glucose, these cells proliferate abnormally, migrate excessively, release inflammatory signals, and drive the angiogenic sprouting that ultimately produces the fragile, leaky vessels characteristic of proliferative disease.

Using a cell counting kit-8 assay to quantify proliferation, transwell assays to measure cell migration, and enzyme-linked immunosorbent assays to detect secreted signaling molecules, the researchers manipulated miR-362-5p levels in these stressed cells. When they inhibited the microRNA, several pathological behaviors were blunted: the high glucose-facilitated proliferation and migration of the endothelial cells were attenuated, and the release of inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha dropped. Levels of vascular endothelial growth factor and angiopoietin-2, two key drivers of pathological angiogenesis, also fell. In other words, silencing this one microRNA appeared to rein in multiple arms of the vascular damage cascade simultaneously, which is precisely the kind of multi-target effect that microRNA biology predicts.

The mechanistic story deepened when the investigators used bioinformatic analysis to predict downstream targets and then validated the interaction experimentally with a dual-luciferase reporter assay and western blotting. These techniques converged on a single gene: CCND2, which encodes cyclin D2, a protein that drives cells through the G1 phase of the cell cycle and is well known for promoting proliferation. The reporter assay demonstrated that miR-362-5p binds directly to the messenger RNA of CCND2, and western blotting confirmed that the microRNA suppresses cyclin D2 protein production. This finding is biologically coherent: by repressing a cell cycle accelerator, elevated miR-362-5p would be expected to alter endothelial cell behavior, and the study’s functional assays showed that the microRNA’s effects on high glucose-induced injury in the retinal endothelial cells were mediated through this target.

The clinical implications are twofold. First, if miR-362-5p holds up in larger and more diverse cohorts, it could become part of a blood-based screening panel for diabetic retinopathy, allowing ophthalmologists to prioritize patients for retinal imaging and earlier intervention. Current screening relies on periodic dilated eye examinations and retinal photography, which are effective but resource-intensive and dependent on patient compliance, a real challenge given that hundreds of millions of people worldwide now live with diabetes. A circulating biomarker that correlates with glycemic control and visual acuity could add an objective, quantitative dimension to risk stratification. Second, the identification of the miR-362-5p and CCND2 axis suggests a potential therapeutic angle: if inhibiting this microRNA protects retinal endothelial cells from high glucose injury in the laboratory, carefully designed inhibitors might one day complement existing treatments such as anti-VEGF injections for proliferative disease.

The researchers are careful to frame these findings as early-stage. The clinical cohort was drawn from a single institution, the First Affiliated Hospital of Henan Medical University, with ethics approval and written informed consent obtained from all subjects in line with the Declaration of Helsinki, and the mechanistic work was performed entirely in cell culture rather than in animal models or human tissue. MicroRNA biomarkers frequently face hurdles on the road to clinical adoption, including variability in how different laboratories isolate and quantify these molecules from blood, the influence of comorbidities, and the need for standardized reference ranges. The study also reports no external funding, and the authors declare no competing interests, which may reassure readers about the independence of the work.

Nevertheless, the study adds a compelling piece to the rapidly growing puzzle of non-coding RNA involvement in diabetic complications. It links a measurable blood signal to a defined molecular pathway inside the very cells that fail in diabetic retinopathy, and it demonstrates that the pathway can be pharmacologically interrogated with existing laboratory tools. As diabetes rates continue to climb globally, the search for biomarkers that catch retinal damage before vision is lost has become a public health priority. Whether miR-362-5p ultimately earns a place in the clinic will depend on validation studies, but this research provides a clear mechanistic rationale and a concrete starting point for the next phase of investigation into protecting the sight of millions of people with diabetes.

Subject of Research: The role of the microRNA miR-362-5p as a biomarker and mechanistic regulator of diabetic retinopathy

Article Title: The clinical role of miR-362-5p in diabetic retinopathy and its mechanism function in high glucose-induced human retinal microvascular endothelial cells

Article References: Guo, H., Shen, W., Wang, X., Meng, X., & Wang, Y. (2026). The clinical role of miR-362-5p in diabetic retinopathy and its mechanism function in high glucose-induced human retinal microvascular endothelial cells. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02542-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02542-1

Keywords: diabetic retinopathy, miR-362-5p, microRNA, CCND2, biomarker, retinal endothelial cells, angiogenesis, inflammation, type 2 diabetes, high glucose, VEGF, diagnostics

The original research, conducted by Zhu and colleagues, examined dendrobine in larval zebrafish subjected to high-glucose conditions, a widely used short-term model of early diabetic retinopathy. The team combined several complementary techniques: imaging of the retinal vasculature, histological examination of retinal tissue, behavioral testing, assays of oxidative stress, and transcriptomic analysis of gene expression. Together, these approaches suggested that dendrobine attenuated a range of abnormalities induced by short-term high-glucose exposure, including the enlargement of retinal vessels that characterizes the earliest stages of the disease. At a concentration of 40 milligrams per liter, the compound appeared to reduce both vascular changes and whole-body glucose levels in the larvae, prompting the authors to propose dendrobine as a candidate therapeutic agent.

Chen’s central criticism concerns the timing of treatment, a detail that may sound technical but carries enormous clinical weight. In the original study, dendrobine and glucose were administered concurrently, from three to six days post-fertilization, meaning the compound was present in the larvae from the very moment hyperglycemic stress began. Dendrobine was never introduced after a retinal abnormality had already been established. The experiment, Chen argues, therefore answers a prevention question rather than a treatment question: it shows that dendrobine can limit injury while high-glucose stress is being induced, but it says nothing about whether the compound can reverse damage that already exists.

This distinction matters because diabetic retinopathy in human patients is almost never caught at the moment metabolic stress begins. By the time most people are diagnosed and treated, vascular and neural changes in the retina have already taken hold. A compound that reduces retinal injury when present from the onset of metabolic stress may not retain the same efficacy once those structural changes are established. Chen points out that the 130 millimolar glucose larval model used in the study was originally developed as a short-term model of early hyperglycemia-related retinal vascular change, and that subsequent work in the field has consistently distinguished such short-term larval immersion models from longer-duration diabetic models designed to study more established retinal complications. The results, in other words, support a protective effect during acute exposure but do not yet demonstrate therapeutic efficacy against established disease.

Chen also notes a second design gap: the study included no dendrobine-only group under normal glucose conditions. This omission is significant because several outcomes interpreted as rescue, including developmental and transcriptomic changes, could plausibly have been influenced by direct effects of dendrobine on normal larval development. Without knowing how the compound behaves in healthy larvae, it is difficult to attribute every observed improvement to protection against glucose injury. Chen proposes that a delayed-treatment design would address both concerns at once: researchers could first document vascular or structural retinal abnormalities after glucose exposure, then initiate dendrobine treatment while maintaining hyperglycemic conditions. Such an approach would more closely mirror the question faced in clinical practice, namely whether a drug can improve retinal injury that is already present rather than prevent it from developing.

The second major issue raised in the letter involves disentangling local retinal effects from systemic glucose lowering. Because dendrobine at 40 milligrams per liter reduced both retinal vessel enlargement and whole-body glucose levels, and because most major outcomes were assessed at the same six-day time point, it remains unclear whether the retinal benefit was a direct effect on eye tissue or simply a downstream consequence of reduced blood sugar. The original authors suggested that retinal improvement might occur before major systemic metabolic change, implying a local retinal mechanism, but as Chen observes, no serial measurements or glucose-matched comparisons were performed to establish that temporal sequence. To their credit, the authors acknowledged that systemic metabolic effects could not be separated from direct retinal actions, but Chen argues that the field needs more: retina-specific assays, direct measurements of retinal dendrobine exposure, or comparisons between experimental groups with similar systemic glucose levels would all help determine whether the compound acts on the retina independently of its glucose-lowering properties.

The third and perhaps most methodologically intricate criticism concerns the transcriptomic data. RNA sequencing in the original study was performed on whole larvae rather than isolated retinal tissue, yet the enriched biological pathways were subsequently linked to retinal protection. Chen emphasizes that whole-organism bulk transcriptomic data cannot identify which tissue or cell type is responsible for differential gene expression without additional spatial or cell-resolved information, a limitation increasingly recognized in the genomics community. Signals arising from the gut, liver, kidney, or other glucose-responsive organs could dominate the expression profile, masking or mimicking retinal-specific changes.

Compounding this concern is a statistical question. Chen notes that neither the main methods section nor the supplementary text of the original study specifies whether the reported transcriptome-wide P values were adjusted for multiple testing. This matters because false-discovery control is a standard requirement when thousands of genes are tested simultaneously; without such correction, apparent pathway enrichments can arise by chance. The quantitative reverse transcription PCR experiments in the original paper do support the direction of expression changes in selected genes, but validating a handful of genes does not establish that the implicated pathways causally mediate the retinal phenotype. At this stage, Chen concludes, the transcriptomic findings are better suited to generating candidate pathways than to identifying what the original authors called precise molecular targets. Retina-specific transcriptomic profiling and functional perturbation of the proposed pathways, such as genetic or pharmacological manipulation in larvae, would provide firmer mechanistic support.

The exchange arrives at a moment of growing interest in natural products as sources of anti-diabetic and neuroprotective compounds. Dendrobine, extracted from Dendrobium orchids long used in traditional medicine, has attracted attention for its reported anti-inflammatory and antioxidant properties, and zebrafish have become a favored platform for early-stage drug screening because their transparent larvae allow direct visualization of developing blood vessels. The high-glucose immersion model offers speed and scale that rodent models cannot match, letting researchers survey vascular changes within days rather than months. Yet the same convenience creates interpretive traps, as this letter makes clear: short exposure windows, whole-organism measurements, and concurrent treatment designs can each blur the line between protection and treatment, between a retinal effect and a systemic one.

None of this diminishes the value of the original work, and Chen is explicit on that point. The study provides useful evidence that dendrobine modifies retinal and systemic responses during acute high-glucose exposure in zebrafish larvae, and the multi-modal approach, spanning imaging, histology, behavior, oxidative stress assays, and transcriptomics, offers a template for how such screens should be conducted. What the letter demands is precision in interpretation: determining whether dendrobine can treat established retinal injury, separating local retinal effects from systemic glucose lowering, and validating the proposed pathways within retinal tissue itself. For the millions of people worldwide at risk of vision loss from diabetic retinopathy, the difference between a preventive compound and a therapeutic one is not academic. It defines the clinical trials that must eventually be run, the patients who could benefit, and the stage of disease at which any new drug must prove itself. This careful critique, published open access in the Journal of Translational Medicine, is a reminder that in translational science, the rigor of interpretation matters as much as the rigor of the experiment.

Subject of Research: Evaluation of dendrobine's protective effects in a zebrafish model of diabetic retinopathy

Article Title: Letter to the Editor regarding “Functions of dendrobine in a zebrafish model of diabetic retinopathy”

Article References: Letter to the Editor regarding “Functions of dendrobine in a zebrafish model of diabetic retinopathy”. (n.d.). https://doi.org/10.1186/s12967-026-08991-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08991-5

Keywords: dendrobine, diabetic retinopathy, zebrafish, high glucose, retinal vasculature, transcriptomics, oxidative stress, glucose lowering, letter to the editor, translational medicine, drug screening, hyperglycemia